DBV Technologies | DBVT - Gross Profit On Sales


DBV Technologies reported $2.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amarin USD 23.17M 961K Dec/2025
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
DBV Technologies USD 2.77M 33.21M Sep/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Insmed USD 356.19M 99.73M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
United Therapeutics USD 683.8M 35.7M Jun/2026